TAP Biosystems has announced that it will be co-presenting a new bioprocess webinar with Irvine Scientific, a major producer of cell culture media, on Wednesday March 12th 2014 at 9 am PST / 12 noon EST / 4 pm GMT.
The live event will detail how to use ambr™ automated micro bioreactor system in alternative semi-continuous modes to mimic perfusion cultures and how this can be used to save time with process optimization and media screening.
Bioprocessing experts, Tom Fletcher, R&D Director at Irvine Scientific and Dr Don Traul, Product Specialist at TAP Biosystems, will present technical data on the use of the ambr 10 - 15ml micro bioreactor system, as a small scale perfusion culture mimic.
To access the webinar, scientists can register at: http://www.tapbiosystems.com/ambr_webinar/ambrIrvine_WebinarPR.htm.
During the webinar, Dr Traul will describe how the ambr system has been utilized as a semi-continuous chemostat model, present field data validating the scalability of the ambr system for continuous culture, and discuss associated DoE applications for media development.
Tom Fletcher will be presenting his use of the ambr system in an alternative semi-continuous mode and will describe the productivity benefits of using ambr to screen a range of candidate media formulations.
Dr Don Traul, TAP Biosystems’ ambr Product Specialist commented: "To date there has been a lack of good scale-down models of large-scale perfusion culture, which has prevented the widespread adoption of this technique as a method for increasing protein yields in biologics production.”
Traul added: “Perfusion culture is a good option for production of unstable or minimally expressing proteins or antibodies and I am pleased to be hosting a webinar alongside Tom Fletcher in which we’ll show proof-of-concept data for use of ambr as a scale down perfusion culture mimic. This will demonstrate how ambr may benefit scientists looking for a strategy to save valuable time with media and process development and will provide them with information on how to rapidly scale up an optimum perfusion culture process for improving production of difficult to manufacture biologics.”